REYKJAVIK, ICELAND and LONDON, UK (August 21, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Commission has approved Mynzepli® as a biosimilar to Eylea® (aflibercept), in a pre-filled syringe and vial.
Related Questions
How will the European approval of Mynzepli® affect Alvotech's and Advanz Pharma's revenue forecasts and stock valuations?
What pricing strategy will be adopted for Mynzepli® compared to the originator Eylea® and other biosimilars, and how might that impact market share?
When is the expected commercial launch in Europe, and what potential reimbursement or payer hurdles could delay adoption?